Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Roberto Fogel

Gastroenterology Lake Worth, FL Medical Doctor

NPI 1083033765 CMS profile 707652

5065 S State Road 7 Ste 201, Lake Worth, FL 33449

Open in the dashboard

General payments

$9,182

323 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberto Fogel of Lake Worth, FL is reported in the CMS Open Payments database as having received $9,182 across 323 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,641 126
2024 General $2,794 90
2023 General $1,661 71
2022 General $1,066 35
2021 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Fogel
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Roberto Fogel were reported at $3,641. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Roberto Fogel Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $19 $352 $106–$1,054 $132
2022 $1,066 $448 $129–$1,270 $149
2023 $1,661 $533 $150–$1,390 $160
2024 $2,794 $605 $160–$1,606 $164
2025 $3,641 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,278 67 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,037 33 payments
  3. Janssen Biotech, Inc. $858 34 payments
  4. Phathom Pharmaceuticals, Inc. $720 14 payments
  5. Madrigal Pharmaceuticals $616 12 payments
  6. Pfizer Inc. $506 38 payments
  7. Celgene Corporation $315 23 payments
  8. Genzyme Corporation $313 10 payments
  9. Gilead Sciences, Inc. $310 9 payments
  10. Ardelyx, Inc. $270 7 payments
  11. Other $1,958 76 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,097 322 payments
  2. Education $85 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $1,073 37 payments
  2. ENTYVIO $997 31 payments
  3. SKYRIZI Immunology $836 23 payments
  4. VOQUEZNA $643 8 payments
  5. TREMFYA $513 16 payments
  6. VELSIPITY $506 38 payments
  7. REZDIFFRA $441 10 payments
  8. STELARA $388 19 payments
  9. SKYRIZI Immunology $357 15 payments
  10. DUPIXENT $313 10 payments
  11. Other $3,910 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,223

Median for Gastroenterology: 569

Drug cost

$69,242

Median for Gastroenterology: $104,976

Branded share of claims

39.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 237 $40,010
Linzess Linaclotide Brand 16 $12,184
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 68 $4,712
Sucralfate Generic 162 $3,747
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 122 $2,022
Omeprazole Generic 205 $2,020
Pantoprazole Sodium Generic 226 $1,763
Esomeprazole Magnesium Generic 55 $1,014
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 35 $626
Dicyclomine Hcl Generic 37 $549

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$23,075

Medicare's payments for the services billed

Medicare patients

125

Average age 71

Services billed

259

69 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 36%
Diabetes 35%
Ischemic heart disease 32%
Depression 31%
Cancer 19%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $430
$430 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $393
$393 — —
SKYRIZI
  • AbbVie, Inc. $347
$347 — —
DUPIXENT
  • GENZYME CORPORATION $127
  • Regeneron Healthcare Solutions, Inc. $43
$171 — —
VELSIPITY
  • PFIZER INC. $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record